EUVIMEDEUVIMED entdecken
Crossref

Integrating Cost Considerations into HIV Care and Prevention to Achieve Population-Level Outcomes

Matthew R Golden iD, Chase A Cannon iD, Timothy W Menza iD, Monisha Sharma iD, Kathryn M Porter, Julia C Dombrowski iD

Clinical Infectious Diseases · 13.11.2026

DOI: 10.1093/cid/ciag713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.11.2026. Verfasst von Matthew R Golden und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US government currently spends >$29 billion annually on HIV treatment, but only 69% of people with diagnosed HIV (PWH) in the US are virally suppressed, a failure partially related to poverty. Medical providers preferentially treat HIV using higher cost medications, and use of higher cost drugs for PrEP is increasing. New, long-acting antiretrovirals (ARVs) have the potential to improve prevention and care while further increasing costs. We believe that the US approach to HIV should change to increase the use of lower cost HIV medications and promote the selective use of long-acting ARVs to treat people who cannot achieve viral suppression using oral drugs. A portion of the money saved through more efficient medication utilization management should be used to improve access to care and provide socioeconomic support to low-income PWH. Together, these changes have the potential to decrease costs, improve health outcomes, and better align spending with patient preferences.

Schlagwörter

Stichwörter der Autor:innen

HIVPrEPantiretroviral drugshealth economicspolicy

Autor:innen und Institutionen

  • Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
  • Public Health - Seattle & King County, Seattle, WA, USA.
  • Department of Global Health, University of WA, Seattle, WA, USA.
  • Treuman Katz Center for Pediatric Bioethics and Palliative Care, Seattle Children's Research Institute, Seattle, WA, USA.

ORCID-Profile: Matthew R Golden, Chase A Cannon, Timothy W Menza, Monisha Sharma, Julia C Dombrowski

Zitieren

APA

Golden, M. R., Cannon, C. A., Menza, T. W., Sharma, M., Porter, K. M., & Dombrowski, J. C. (2026). Integrating Cost Considerations into HIV Care and Prevention to Achieve Population-Level Outcomes. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag713

Vancouver

Golden MR, Cannon CA, Menza TW, Sharma M, Porter KM, Dombrowski JC. Integrating Cost Considerations into HIV Care and Prevention to Achieve Population-Level Outcomes. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag713

BibTeX
@article{Golden2026,
  author = {Golden, Matthew R and Cannon, Chase A and Menza, Timothy W and Sharma, Monisha and Porter, Kathryn M and Dombrowski, Julia C},
  title = {Integrating Cost Considerations into HIV Care and Prevention to Achieve Population-Level Outcomes},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag713}
}
Kostenlos starten →